Search
for
Sort by
Research 31–60 of 788
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- The Sebaceous Gland - Friend or Foe?
- Alopecia Areata
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- The genetic basis of dermatophytosis skin infection susceptibility
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Recent advances in the genetics of alopecia areata
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Association between genetically predicted rheumatoid arthritis and alopecia areata: a two-sample Mendelian randomization study
- JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
- 217 The adenosine-generating ecto-enzyme CD73 regulates human hair growth
- Study on the zona pellucida 4 (ZP4) gene sequence and its expression in the ovaries of patients with polycystic ovary syndrome
- Effect of Topical Gel Administration of Secretome Hypoxia Mesenchymal Stem Cells (SH-MSCs) on IL-10 and TNF- α Gene Expression (In Vivo Experimental Study in Male Rats of Wistar Strains Model of Fluconazole-Induced Alopecia)
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review